603301-02-6

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromofuro[3,2-c]pyridin-4(5H)-one is used as a key intermediate in the synthesis of various pharmaceutical compounds for its unique structure and reactivity. It contributes to the development of new drugs by providing a foundation for the creation of complex molecular structures with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 7-Bromofuro[3,2-c]pyridin-4(5H)-one is utilized as a versatile building block for constructing a wide range of complex organic molecules. Its unique structure allows for various chemical reactions, enabling the synthesis of compounds with diverse applications in different industries.
Used in Medicinal Chemistry Research:
7-Bromofuro[3,2-c]pyridin-4(5H)-one is employed as a valuable tool in medicinal chemistry research, where it aids in the discovery and development of new drugs. Its unique structure and reactivity make it an ideal candidate for exploring novel chemical pathways and designing innovative therapeutic agents.
Used in Drug Discovery:
In drug discovery, 7-Bromofuro[3,2-c]pyridin-4(5H)-one plays a crucial role as a starting material for the synthesis of potential drug candidates. Its unique structural features and reactivity enable the development of new compounds with improved pharmacological properties and therapeutic efficacy.

InChI:InChI=1/C7H4BrNO2/c8-5-3-9-7(10)4-1-2-11-6(4)5/h1-3H,(H,9,10)

Upstream product

• 26956-43-4 5H-furo[3,2-c]pyridin-4-one 
• 119924-26-4 (E)-3-(2-furanyl)-2-propenoyl azide 
• 539-47-9 3-(fur-2-yl)crotonic acid 
• 98-01-1 furfural 

Downstream Products

• 603302-76-7 furo[3,2-c]pyridine-7-carbonitrile 
• 603302-91-6 (furo[3,2-c]pyridin-7-yl)methanol 
• 603300-96-5 7-bromofuro[3,2-c]pyridine 
• 603301-06-0 4,7-dibromofuro[3,2-c]pyridine 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

The development of potent and selective bisarylmaleimide GSK3 inhibitors

Many 3-aryl-4-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl) maleimides exhibit potent GSK3 inhibitory activity (50), although few show significant selectivity (>100 ×) versus CDK2, CDK4, or PKCβII. However, combining 3-(imidazo[1,2-a]pyridin-3-yl), 3-(pyrazolo[1,5-a]pyridin-3-yl) or aza-analogs with a 4-(2-acyl-(1,2,3,4- tetrahydro[1,4]diazepino[6,7,1-hi]indol -7-yl)) group on the maleimide resulted in very potent inhibitors of GSK3 (≤5 nM) with >160 to >10,000-fold selectivity versus CDK2/4 and PKCβII. These compounds also inhibited tau phosphorylation in cells and were effective in lowering plasma glucose in a rat model of type 2 diabetes (ZDF rat).

PURINE DERIVATIVES AS KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula I.